AR085302A1 - Metodo de produccion de anticuerpos sialilados - Google Patents

Metodo de produccion de anticuerpos sialilados

Info

Publication number
AR085302A1
AR085302A1 ARP120100573A ARP120100573A AR085302A1 AR 085302 A1 AR085302 A1 AR 085302A1 AR P120100573 A ARP120100573 A AR P120100573A AR P120100573 A ARP120100573 A AR P120100573A AR 085302 A1 AR085302 A1 AR 085302A1
Authority
AR
Argentina
Prior art keywords
antibody
domain
expressing
stirated
antibodies
Prior art date
Application number
ARP120100573A
Other languages
English (en)
Inventor
Beatrice Cameron
Bruno Genet
Fabienne Soubrier
Francis Blanche
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR085302A1 publication Critical patent/AR085302A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Abstract

La presente hace referencia a un método para producir un anticuerpo lgG, donde el menos 80% de dicho anticuerpo comprende un oligosacárido en forma de dos antenas, complejo, que contiene dos residuos de ácido siálico, anclados al dominio Fc del anticuerpo. Dicho método comprende las etapas de introducir una mutación en el dominio Fc del anticuerpo, y expresar el anticuerpo mutante en una célula que expresa una actividad b galactosiltransferasa y sialiltransferasa.Reivindicación 1: Un método para producir un anticuerpo lgG, donde al menos 80 % de dicho anticuerpo comprende un oligosacárido en forma de dos antenas, complejo, que contiene dos residuos de ácido siálico, anclados a cada dominio Fc del anticuerpo, comprendiendo dicho método las etapas de: a) introducir una mutación en dicho dominio Fc de dicho anticuerpo, y b) expresar el anticuerpo mutante obtenido en la etapa a) en una línea celular que expresa actividad b galactosiltransferasa y sialiltransferasa.
ARP120100573A 2011-02-24 2012-02-22 Metodo de produccion de anticuerpos sialilados AR085302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305200 2011-02-24
EP11306090 2011-09-01

Publications (1)

Publication Number Publication Date
AR085302A1 true AR085302A1 (es) 2013-09-18

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100573A AR085302A1 (es) 2011-02-24 2012-02-22 Metodo de produccion de anticuerpos sialilados

Country Status (6)

Country Link
US (1) US20140046032A1 (es)
EP (1) EP2678357A1 (es)
JP (1) JP2014508759A (es)
AR (1) AR085302A1 (es)
TW (1) TW201241182A (es)
WO (1) WO2012113863A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2983701A2 (en) 2013-03-11 2016-02-17 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
ES2802274T3 (es) * 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2014186310A1 (en) * 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CN105324487B (zh) * 2013-05-29 2020-01-17 豪夫迈·罗氏有限公司 唾液酸化的定量控制
WO2015001033A1 (en) 2013-07-05 2015-01-08 F. Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) * 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SG10201808158UA (en) 2014-03-19 2018-10-30 Genzyme Corp Site-specific glycoengineering of targeting moieties
CN108064266A (zh) 2014-07-21 2018-05-22 格利科斯芬兰公司 在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
CN107429237B (zh) 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
FR3080376B1 (fr) * 2018-04-20 2022-12-09 Lab Francais Du Fractionnement Autoanticorps hautement sialyles et leurs utilisations
WO2023086793A1 (en) * 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
DE60236182D1 (de) 2001-09-14 2010-06-10 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
JP2006518372A (ja) 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
ES2543685T3 (es) * 2005-06-30 2015-08-21 Janssen Biotech, Inc. Métodos y composiciones con actividad terapéutica mejorada
SI1945665T1 (sl) 2005-10-21 2012-03-30 Genzyme Corp Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
KR101591223B1 (ko) 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US10167332B2 (en) 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2666308C (en) * 2006-10-26 2014-09-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2091969A4 (en) 2006-10-27 2010-05-12 Univ Rockefeller POLYPEPTIDES WITH IMPROVED INFLAMMATORY INHIBITION AND REDUCED CYTOTOXIC PROPERTIES AND RELATED METHODS THEREFOR
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
CN111909273B (zh) 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
EA201070479A1 (ru) 2007-10-15 2010-12-30 Сентокор Орто Байотек Инк. Человеческие антиамилоидные антитела, композиции, способы и их применение
CA2703045C (en) 2007-10-25 2017-02-14 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
EP2226081A4 (en) 2007-10-25 2011-10-12 Univ Kagoshima PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE
JP5185946B2 (ja) 2007-10-29 2013-04-17 Ｔａｏヘルスライフファーマ株式会社 抗体及びその利用
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
KR101629365B1 (ko) 2007-12-11 2016-06-14 글락소 그룹 리미티드 항원 결합성 단백질
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Also Published As

Publication number Publication date
EP2678357A1 (en) 2014-01-01
JP2014508759A (ja) 2014-04-10
US20140046032A1 (en) 2014-02-13
TW201241182A (en) 2012-10-16
WO2012113863A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
AR085302A1 (es) Metodo de produccion de anticuerpos sialilados
PH12019550056A1 (en) Improved process for the production of fucosylated oligosaccharides
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
MY183415A (en) Anti-c5 antibodies and methods of use
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
AR087608A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
AR083114A1 (es) Produccion de anticuerpos de fucosa baja en celulas de rata h4-ii-e
BR112017021255A2 (pt) microrganismo modificado para a produção otimizada de 2,4-di-hidroxibutirato
BR112013025753A8 (pt) Métodos para aprimoramento do rendimento de produto e produção em um micro-organismo através da adição de aceptores de elétrons alternativos
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
AU2011372711B2 (en) Method for processing mesenchymal stem cells and the use thereof in the treatment of diseases associated with oxidative stress
UA110946C2 (uk) Спосіб одержання лігніну
WO2011131746A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
EA201890345A3 (ru) Способ получения сахарного спирта из биомассы
BR112016010340A2 (pt) novos métodos para se produzir tert ativa
BR112014014151A2 (pt) células fúngicas e processos de fermentação
MX346518B (es) Metodos de desarrollo de variantes de terpeno sintasa.
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
BR112016009365A2 (pt) Método para aumentar, melhorar e estender a produção de etanol e método para diminuir as concentrações finais de dp2 em um produto de fermentação
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
MX2019007411A (es) Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
BR112015005081A8 (pt) Método para produzir um polissacarídeo capsular tendo um sorotipo de pneumococo
BR112018007590A2 (pt) método para produzir proteína de fusão que tem domínio fc de igg

Legal Events

Date Code Title Description
FB Suspension of granting procedure